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ABSTRACT
Introduction: Second-hand smoke (SHS) exposure
is estimated to kill 600 000 people worldwide
annually. The WHO recommends that smoke-free
indoor public environments are enforced through
national legislation. Such regulations have been
shown to reduce SHS exposure and, consequently,
respiratory and cardiovascular morbidity. Evidence of
particular health benefit in children is now emerging,
including reductions in low birthweight deliveries,
preterm birth and asthma exacerbations. We aim to
comprehensively assess the impact of smoke-free
legislation on fetal, infant and childhood outcomes.
This can inform further development and
implementation of global policy and strategies to
reduce early life SHS exposure.
Methods: Two authors will search online databases
(1975–present; no language restrictions) of
published and unpublished/in-progress studies, and
references and citations to articles of interest. We
will consult experts in the field to identify additional
studies. Studies should describe associations
between comprehensive or partial smoking bans in
public places and health outcomes among children
(0–12 years): stillbirth, preterm birth, low birth
weight, small for gestational age, perinatal mortality,
congenital anomalies, bronchopulmonary dysplasia,
upper and lower respiratory infections and wheezing
disorders including asthma. The Cochrane
Effectiveness Practice and Organisational Care
(EPOC)-defined study designs are eligible. Study
quality will be assessed using the Cochrane 7-
domain-based evaluation for randomised and clinical
trials, and EPOC criteria for quasiexperimental
studies. Data will be extracted by two reviewers and
presented in tabular and narrative form. Meta-
analysis will be undertaken using random-effects
models, and generic inverse variance analysis for
adjusted effect estimates. We will report sensitivity
analyses according to study quality and design
characteristics, and subgroup analyses according to
coverage of ban, age group and parental/maternal
smoking status. Publication bias will be assessed.
Ethics and dissemination: Ethics assessment is
not required.
Results: Will be presented in one manuscript.
The protocol is registered with PROSPERO,
registration number CRD42013003522.
INTRODUCTION
Tobacco use kills more than ﬁve million people
annually, making it the leading global cause of
preventable death.1 It is estimated that second-
hand smoke (SHS) exposure kills an additional
600 000 people worldwide each year, including
165 000 children under 15 years.1 2 Among
non-smoking adults, SHS exposure further-
more increases the incidence of asthma, lung
cancer and ischaemic heart disease.2 In an
attempt to reduce this substantial burden on
second-hand or passive smokers, the WHO has
recommended that smoke-free indoor public
environments are enforced through national
legislation and that educational strategies are
pursued in parallel to reduce SHS exposure in
the home.3 Studies have since shown that
ARTICLE SUMMARY
Article focus
▪ Second-hand smoke exposure is associated with
a range of adverse health outcomes among
infants and children.
▪ Smoke-free legislation effectively reduces expos-
ure to second-hand smoke and evidence for par-
ticular benefits for child health are now emerging.
▪ A comprehensive estimate of the effects of
smoke-free legislation on perinatal and paediatric
health is currently lacking.
Key messages
▪ We will undertake a systematic review and meta-
analysis to comprehensively assess the impact of
smoke-free legislation on perinatal and paediatric
health.
▪ The results can inform the development and
implementation of global policy and strategies to
reduce second-hand smoke exposure in early life.
Strengths and limitations of this study
▪ We will interrogate a large number of online data-
bases using an inclusive search strategy to iden-
tify the relevant literature. All Cochrane Effective
Practice and Organisation of Care (EPOC) designs
will be eligible for inclusion. Published guidelines
will direct quality assessment and reporting.
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smoking bans effectively reduce SHS exposure, even in the
absence of an overall decline in smoking prevalence in the
population.4 More importantly, consistent health effects
have been reported in a recent Cochrane review summaris-
ing 25 studies including reductions in respiratory symp-
toms, sensory symptoms and admissions for acute
myocardial infarction (AMI).4 These effects have since
been reproduced by others,5–7 while additional studies also
demonstrated reductions in sudden cardiac arrest and mor-
tality from AMI in response to implementation of smoke-
free legislation.8 9
As developing individuals, children are particularly vul-
nerable to the negative effects of SHS, which may even
ensue before birth.10–12 Furthermore, they are unable to
inﬂuence their own degree of exposure. Antenatal SHS
exposure puts unborn babies at risk for stillbirth,13 preterm
delivery,14 growth retardation,12 15 congenital anomalies,15 16
bronchopulmonary dysplasia17 and respiratory infections
and asthma in childhood.11 18 Worldwide, at least 40% of
children are regularly exposed to SHS after birth, addition-
ally predisposing them to upper and lower respiratory infec-
tions as well as asthma.2 Children thus bear an important
part of the disease burden associated with SHS and are
likely to particularly beneﬁt from restrictive legislation.
Indeed, several recent studies provide evidence for beneﬁ-
cial effects of smoke-free laws on infant and child health.
Epidemiological evaluations of the 2006 Scottish smoking
ban have demonstrated reductions in low birth weight,
preterm birth and childhood asthma hospitalisations follow-
ing its introduction.19 20 These results have now been con-
ﬁrmed in several follow-up studies.21 22
Despite this increasing evidence for particular health
beneﬁts of smoke-free legislation in children, the cur-
rently available systematic reviews assessing its health
effects in general have not included any studies on
perinatal or paediatric outcomes.4 23 24 A comprehensive
estimate of the beneﬁts associated with smoke-free legis-
lation in newborns and children will inform the develop-
ment and implementation of global policy and strategies
to further reduce SHS exposure in this particularly
vulnerable population. Therefore, we will undertake a
systematic review and meta-analysis of studies on fetal,
infant and child-health outcomes related to the intro-
duction of smoke-free legislation in order to obtain the
most comprehensive assessment to date of its effective-
ness in improving the health of babies and children
worldwide.
METHODS AND ANALYSIS
Design
Systematic review and meta-analysis.
Eligibility criteria
Types of interventions
▸ Comprehensive (eg, bars, restaurants and working
space) or partial (eg, working space only) smoking
ban in public places at the national, state, city or
community level.
Types of studies
▸ In keeping with the Cochrane Effective Practice and
Organisation of Care (EPOC) guidelines that have
set the standard for reviews of interventions designed
to improve delivery of effective health services, only
the following study designs will be considered for
inclusion: (cluster) randomised controlled trials
(RCTs), controlled clinical trials (CCTs), quasiexperi-
mental studies, controlled before-and-after studies,
interrupted time series (ITS) analysis.25 For non-
randomised studies, comparisons may include either
a similarly aged population evaluated in the time
frame preceding the introduction of the smoking
ban in the same region, or a similar population evalu-
ated during the same time frame in an adjacent geo-
graphical area where a smoking ban was not in place.
▸ Modelling, case–control, cohort, cross-sectional
and uncontrolled before-and-after studies are
excluded, given the difﬁculty in attributing caus-
ation from such studies.
Types of participants
▸ Fetuses >20 weeks gestation
▸ Newborns >20 weeks gestation
▸ Children aged 0–12 years. In order to minimise the
confounding effect of self-smoking, we will restrict
our analyses to children aged 12 years and under.
Types of outcome measures
Outcome measures should preferably be reported or
documented by a health worker; alternatively, parent-
reported outcomes, parent-reported physician diagnoses
or diagnoses based on medication use or prescriptions
(eg, inhaled corticosteroids as a surrogate for asthma diag-
nosis) are acceptable. Outcomes may be deﬁned as abso-
lute (eg, incidence) or relative disease occurrence (eg,
relative risk and OR), or by associated health facility use
(eg, doctor or emergency department visits and hospital-
isation). Outcomes of interest are selected based on their
relevance to fetal, infant and/or paediatric health and
their recognised association between antenatal and/or
postnatal SHS exposure. In addition, selection of primary
outcomes is based on the magnitude of their burden for
paediatric health, as well as their recognised reduction
after the introduction of smoke-free legislation as shown
by at least one high-quality study.
▸ Primary outcomes
– Preterm birth (live-birth between the 20th and
37th weeks of gestation)
– Low birth weight (<2500 g)
– Asthma (recurrent or persistent wheezing in chil-
dren aged 5 years or older)
▸ Secondary outcomes
– Perinatal outcomes
‐ Stillbirth (intrauterine death of a fetus
>20 weeks gestational age)
‐ Early neonatal death (<1 week postnatally)
‐ Perinatal death (stillbirth + neonatal death)
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‐ Late neonatal death (death 7–28 days postnatally)
‐ Neonatal death (death 0–28 days postnatally)
‐ Very preterm birth (<32 weeks’ gestational age)
‐ Very low birth weight (<1500 g)
‐ Extremely low birth weight (<1000 g)
‐ Small for gestational age (birth weight <10th
percentile for gravidity, ethnicity and sex)
‐ Congenital anomalies
‐ Bronchopulmonary dysplasia
– Childhood outcomes
‐ Upper respiratory, infectious (pooled)
– Coryza, pharyngitis, tonsillitis, laryngi-
tis/tracheitis, sinusitis, acute otitis
media, inﬂuenza
‐ Upper respiratory, non-infectious
– Otitis media with effusion
‐ Lower respiratory, infectious (pooled)
– Bronchitis/bronchiolitis, whooping
cough, pneumonia
‐ Lower respiratory, non-infectious
Wheezing (≥2 wheezing episodes in chil-
dren aged 4 years or younger)
Chronic cough (cough lasting >4 weeks)
▸ Outcomes not included in the review
– Surrogates and intermediates for adverse
outcome (eg, intima media thickness, blood pres-
sure, antioxidant activity)
– Smoke-related behaviours (eg, teenage smoking,
attitude towards smoking, stopping behaviour)
– Measures of smoke exposure (eg, smoke expos-
ure in the home, environmental nicotine mea-
sures, cotinine levels)
– Economic data (costs, cost-effectiveness)
When outcome deﬁnitions used in selected reports
differ from the criteria outlined above, two authors ( JVB
and UN) will make a decision regarding their inclusion in
any meta-analyses. This will be based on the degree of
deviation from the deﬁned outcome criteria, and the
expected effect that this may have on the analyses. A third
author will be consulted to resolve any disagreement.
Additional sensitivity analyses will be considered to explore
the effect of inclusion of different outcome deﬁnitions.
Search methods
▸ Eligible study reports will be identiﬁed as follows:
– Published work will be searched for in the follow-
ing databases: Cochrane Library (CENTRAL),
Medline, EMBASE, AMED, CAB, Global Health,
CINAHL, WHO Global Health Library (in add-
ition to MEDLINE covering AIM (AFRO), LILACS
(AMRO/PAHO), IMEMR (EMRO), IMSEAR
(SEARO), WPRIM (WPRO), WHOLIS (KMS),
SciELO), IndMED, TRIP, ISI Web of Science,
KoreaMed, Google Scholar
– In addition, reference lists of articles of interest
and citations to included articles will be screened
for additional eligible published studies
– Unpublished and in-progress studies will be identi-
ﬁed from the following trial registries:
ClinicalTrials.gov; ISRCTN Register; WHO
International Clinical Trials Registry Platform; EU
Clinical Trials Register; Current Controlled Trials;
Australian New Zealand Clinical Trial Registry; Pan
African Clinical Trials Registry; Chinese Clinical
Trial Register; Clinical Trials Register India;
Brazilian Clinical Trials Registry; Clinical Research
Information Service, Republic of Korea; Cuban
Public Registry of Clinical Trials; German Clinical
Trials Register; Iranian Registry of Clinical Trials;
The Netherlands’ Trialregister; Sri Lanka Clinical
Trials Registry; UMIN Clinical Trials Registry
– Expert consultation
▸ Search strategy: see online supplementary appendices
1 and 2
▸ Restrictions
– Time span: 1975-current (rationale: the ﬁrst
regional smoking ban was introduced in 1975 in the
US state of Minnesota)26
– Language: none (for foreign language papers trans-
lations will be sought)
Study selection
Two authors ( JVB and UN) will search databases and
screen titles and abstracts for potentially eligible studies.
Disagreement will be resolved by consensus, or arbitra-
tion involving a third author where necessary. Full text
articles will be retrieved for selected studies, and two
authors ( JVB and UN) will assess whether these meet
inclusion criteria. Disagreement will be resolved by dis-
cussion among reviewers, with referral to a third author if
necessary. Reasons for exclusion of studies will be noted.
Quality assessment and analysis
Study quality will be assessed using the Cochrane hand-
book 7-domain-based evaluation for RCTs, quasi-RCTs
and CCTs (Cochrane handbook, table 8.5.a).27 For con-
trolled before-and-after studies and ITS analyses, EPOC
guidelines will be used.28 We will grade each parameter
of trial quality: A, low risk of bias; B, moderate risk of
bias; C, high risk of bias and an overall assessment for
each controlled trial using the same three criteria will be
made. Risk of bias will be assessed in part by recording
design features (assessed by a formal list in the
Cochrane handbook, table 13.2.a) as well as by whether
or not confounding is accounted for.27 The primary con-
founder considered is maternal or parental smoking.
Documentation of maternal/parental smoking accord-
ing to smoke-free legislation status will be assessed, as
well as adjustment of the ﬁnal analyses for a potential
confounding effect of this variable. All assessments of
study quality will be performed by two authors ( JVB and
UN), with any disagreement resolved by consensus, or
arbitration involving a third author where necessary.
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Data extraction
Data will be extracted from selected papers by two
reviewers ( JVB and UN), with any disagreement resolved
by consensus, or arbitration involving a third author
where necessary. Corresponding authors of eligible
studies will be contacted to clarify any ambiguities. The
following information will be extracted:
1. Geographical setting (eg, country and city)
2. Reported study type (eg, RCT and quasiexperi-
mental study)
3. Design features (assessed by a formal list in the
Cochrane handbook, table 13.2.a).27
4. Eligible population size
5. Included population size/number of clusters +
cluster sizes
6. Relevant demographic characteristics (including
age)
7. Description of intervention (including locations
where ban was in effect (eg, bars, workplace and
government buildings) and level of enforcement)
8. Inclusion/exclusion criteria
9. Outcomes
10. Effect sizes (univariate + multivariate)
11. Confounders adjusted for (eg, parental smoking)
12. Bias assessment
13. Adverse effects
14. Follow-up rate and handling of dropouts
15. Follow-up period
Data analysis
Data will be presented in tabular and narrative forms. If
possible, meta-analysis will be performed on similar
studies reporting main, primary and secondary outcomes,
and be presented in forest plots. Choice of the statistical
tests used will depend on the nature of the outcome vari-
able. We will apply a random effects model in all analyses,
given the expected degree of heterogeneity in the popu-
lation and design between studies. Heterogeneity will be
assessed both qualitatively and quantitatively using the
I² statistic. Meta-analysis will not be undertaken when I² is
equal to or greater than 75%. Where possible, adjusted
effect estimates will be pooled in meta-analyses using
generic inverse-variance analysis. Adjusted effect esti-
mates derived from the most adjusted model in the ori-
ginal paper will be selected for these analyses. Point
estimates and 95% CIs will be reported for all analyses.
Sensitivity analyses will be performed in subgroups of
study quality and of design characteristics (randomised vs
non-randomised; prospective vs retrospective). If pos-
sible, analyses will be performed in subgroups made
according to the following deﬁning parameters: setting
of smoking restriction (comprehensive vs location-
speciﬁc (eg, working space, bars and restaurants)), age of
study individuals (under 5 vs 5 years and older), smoking
status in the home or maternal smoking for perinatal out-
comes. For meta-analyses of adjusted effect estimates, an
additional sensitivity analysis will be performed according
to whether or not maternal or parental smoking was part
of the adjusted model in the original study.
For any meta-analysis that includes 10 or more studies,
publication bias will be assessed visually through Funnel
plots and tested by Egger’s regression test and Begg’s
rank correlation test.29 30 All statistical analyses will be
performed using Stata.
ETHICS AND DISSEMINATION
Ethical issues
As no primary data collection will be undertaken, no
additional formal ethical assessment and informed
consent are required.
Publication plan
The systematic review protocol is registered with the
PROSPERO International Prospective Register of
Systematic Reviews (http://www.crd.york.ac.uk/prospero).
Findings will be summarised in a single manuscript.
Timeline
Start date: 1 January 2013
Finishing date: 31 March 2014
Reporting date: 31 March 2014
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